SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Disruptions to Middle Eastern LNG supply and risks to shipping through the Strait of Hormuz have traders looking to U.S. exporters such as NextDecade as potential long-term beneficiaries. The bullish view is tempered by the fact that Rio Grande is still under construction and production is not expected until 2027, so traders debate how much of the supply shock NEXT can capture in the near term.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,075,763,011.6159 in circulation. The last known price of Algorand is 0.09537939 USD and is up 2.17 over the last 24 hours. It is currently trading on 586 active market(s) with $72,099,657.31 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

Traders are debating whether ALGOs recovery from recent lows signals a durable bottom and a broader altcoin-season move, with bulls pointing to technical setups, accumulation, and its quantum-resistant and tokenization use cases. Skeptics counter that ALGO has repeatedly failed to hold rallies and cite its long-term underperformance and token supply concerns.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms quarterly results and outlook are driving attention, with traders focusing on stronger enterprise growth, AI-product adoption and a higher full-year forecast; bullish reactions contrast with concerns about modest overall growth and competitive pressure. The Anthropic stake and a potential IPO are also cited as a speculative source of value, though traders disagree on how much it may benefit Zoom.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl is drawing attention after Q3 results beat expectations, with traders highlighting AUM growth, fee earnings and managements upbeat outlook on dividend coverage and undeployed capital. The positive reaction is tempered by continuing concerns about fund redemptions and private-credit exposure, including data-center financing risks.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is drawing attention after reports that CEO Julie Sweet and a director made open-market share purchases, alongside bullish call-option activity. Many traders view the insider buying as a confidence signal, while others are taking profits or positioning for a pullback after the stocks recent rise.

Akamai Technologies, Inc. is the cybersecurity and cloud computing company that powers and protects business online. The market security solutions, superior threat intelligence, and global operations team provide defense in depth to safeguard enterprise data and applications everywhere. The firm full-stack cloud computing solutions deliver performance and affordability on the world’s most distributed platform. The global enterprises trust Akamai to provide the industry reliability, scale, and expertise they need to grow their business with confidence. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

A multiyear Anthropic cloud-infrastructure deal has put Akamais AI-cloud ambitions in focus, but shares gave back much of their initial rally. Traders are split between viewing the contract as validation of a growth pivot and worrying about upfront capital spending, delayed returns, and reliance on one major customer.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,098,130.40630647. The last known price of Pepe is 0.00000495 USD and is up 9.16 over the last 24 hours. It is currently trading on 729 active market(s) with $1,489,033,091.54 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPE is drawing attention for volatile price swings and repeated attempts to reclaim nearby resistance, with traders debating whether recent rebounds signal a breakout or another fade. Some see relative strength and are buying dips, while others point to selling pressure and continued sensitivity to Bitcoin and broader crypto-market moves.

Sky (SKY) is a cryptocurrency and operates on the Ethereum platform. Sky has a current supply of 23,452,431,915.60596656 with 23,422,827,962.33348843 in circulation. The last known price of Sky is 0.06706993 USD and is up 0.91 over the last 24 hours. It is currently trading on 257 active market(s) with $49,629,100.47 traded over the last 24 hours. More information can be found at https://sky.money/.

Skycoin

Traders are focused on reports of Galaxy Digital adding Skys yield-bearing token to its treasury and accepting it as collateral, with the broader institutional tie-up seen as a boost to the Sky ecosystem. Bulls point to rising volume and a possible breakout, while others caution that the recent rally could pull back; short-squeeze claims remain speculation.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,177.65528711 USD and is down -1.08 over the last 24 hours. It is currently trading on 12773 active market(s) with $46,266,908,298.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin discussion is dominated by the reported Binance hack, which has raised concerns about exchange security, customer withdrawals and possible selling pressure across crypto. Traders are divided: some see Bitcoin holding up and treat the dip as a buying opportunity, while others expect further downside as confidence remains shaken.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoins choppy, mostly range-bound trading and repeated difficulty clearing resistance dominate the discussion. Some traders view the consolidation as a chance to accumulate, while others are frustrated by the weak performance and expect further downside.

statis crypto Watchlist

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026, following the release of its third quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or...

Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?

PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.

The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology

AstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive...

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

Puma Biotechnology Initiates ALISCA-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. The...

Puma Biotechnology to Present at H.C. Wainwrights 28th Annual Global Investment Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 3:30 p.m. ET on Monday, September 14, at the H.C. Wainwright 28th Annual Global Investment Conference...

Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 33,550 shares of Puma common stock to five new non-executive...

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Puma Biotechnology Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$PBYI $HURA $ELSA.X  I am definitely going to start focusing on biotech's more like I was originally. I've got my long terms in gold space and energy, but I feel like my lack of focus on healthcare and biotech's has left me missing some key moves I anticipated in the past. So far I've caught PACB NAUT QSI from the beginning of Oct. 🍻👍🏼

Feed

News

Sentiment

Earnings

Fundamentals

Info

PBYI Puma Biotechnology Inc

Fundamentals

Latest PBYI News